ClinicalTrials.gg
CompletedNCT03278028Updated Apr 9, 2019Results posted

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

A Phase 2 interventional study of A-101 Topical Solution and A-101 Vehicle Solution in Common Wart, sponsored by Aclaris Therapeutics, Inc.. Completed at 16 sites in United States. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2019-04-09.

Sponsored by Aclaris Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
8 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 59 studies in Warts with a site in United States — 7 open to participants now, 10 under way, 4 of them phase 3. Warts · United States.

Enrollment
13th of 58
159 · median 80
Started
2017
with 3 others
Phase 2
23 of 59
1 open now
Registered
34th of 59
by date
Lead sponsor
6 of 59
Aclaris Therapeutics, Inc.

Among the 59 studies in Warts with a site in United States, this one is the 13th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2017, is one of 23 in phase 2, and was the 34th registered.

Warts

172 studies on the registry are indexed under Warts; 36 are open to participants now.

Browse Warts studies →

Open to participants now

7 of the 59 studies in Warts with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Warts studies recruiting now, 11 (58%) set no upper age limit and 8 (42%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 8 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Warts with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.

Read the detailed description

The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.

The secondary objectives of this study are to evaluate the clinical effect of A-101 when applied to all treated Warts (Target Warts plus Non-Target Warts) twice a week, duration of response in all treated Warts (Target Warts plus Non-Target Warts), and safety of A-101.

03

Conditions studied

  • Common Wart

Browse trials for

04

Who can participate

Ages eligible
8 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is able to comprehend and is willing to sign an /assent for participation in this study.
  • Male or female ≥ 8 years old.
  • Subject chemistry and complete blood count results are within normal limits. If any of the laboratory values are outside normal range, the treating investigator must assess the value/s as NOT and document this in the subject's medical chart in order for the subject to be eligible for randomization.
  • Woman of (WOCBP) must have a negative urine pregnancy test within 14 days of the first application of study drug and agree to use an active method of for the duration of the study.
  • Subject is non-pregnant and non-lactating.
  • Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair the evaluation of any Target and Non-Target Warts or which exposes the subject to an unacceptable risk by study participation.
  • Subject is willing and able to follow all study instructions and to attend all study visits.

Exclusion criteria

Exclusion Criteria:

  • Subject has clinically atypical warts on the trunk or extremities.
  • Subject is (e.g., due to chemotherapy, systemic , genetic immunodeficiency, transplant status, etc.)
  • Subject has a history of (HIV) infection
  • Subject has had any Human Papilloma Virus (HPV) vaccine within 1 year prior to Visit 1
  • Subject has a history of sensitivity to any of the ingredients in the study medications.
  • Subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations.
  • Participation in another therapeutic drug trial in which administration of an investigational study medication occurred with 30 days prior to Visit 1.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    Active

    A-101 Topical Solutions

    Drug: A-101 Topical Solution

  • Placebo comparator
    Vehicle

    Vehicle

    Drug: A-101 Vehicle Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Physician's Wart Assessment

    Physician's Wart Assessment Grade Descriptor 0 Clear: No visible wart. No further treatment is indicated. 1. Near Clear: A visible wart that is less than 3 mm in maximal diameter (or length) 2. A visible wart ≥ 3 mm and \< 6 mm in maximal diameter (or length) 3. A visible wart ≥ 6 mm in maximal diameter (or length)

    Time frame: Day 57

07

Results

Posted Mar 29, 2019

Participant flow

Participant flow — Overall Study
MilestoneActiveVehicle
Started8178
Completed7776
Not completed42
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject31
Withdrew: Pregnancy01

Outcome measures

PrimaryPhysician's Wart Assessment

Physician's Wart Assessment Grade Descriptor 0 Clear: No visible wart. No further treatment is indicated. 1. Near Clear: A visible wart that is less than 3 mm in maximal diameter (or length) 2. A visible wart ≥ 3 mm and \< 6 mm in maximal diameter (or length) 3. A visible wart ≥ 6 mm in maximal diameter (or length)

Time frame:
Day 57
Reported as:
Mean · score on a scale
Physician's Wart Assessment
score on a scaleActiveVehicle
Physician's Wart Assessment1.52 ± 1.062.23 ± 0.66

Adverse events

Collected over 78 days; Treatment-emergent adverse events (TEAEs) had a start date on or after the date of Visit 2 (study day 1) and treatment-emergent serious adverse events had a start date on or after the date of Visit 1 (Screening). Collection continued through visit 11 (Day 78). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active0/81 (0%)0/81 (0%)28/81 (34.6%)
Vehicle0/78 (0%)0/78 (0%)19/78 (24.4%)
Most frequent other events
Showing 10 of 45
Most frequent other events
EventActiveVehicle
NasopharyngitisInfections and infestations5/814/78
Upper Respiratory Tract InfectionInfections and infestations4/814/78
ConstipationGastrointestinal disorders0/812/78
Gastroenteritis ViralInfections and infestations2/811/78
InfluenzaInfections and infestations2/810/78
InjuryInjury, poisoning and procedural complications2/810/78
HeadacheNervous system disorders2/811/78
Skin HypopigmentationSkin and subcutaneous tissue disorders2/810/78
HypertensionVascular disorders2/810/78
Food AllergyImmune system disorders0/811/78

Baseline characteristics

Age, Continuous
Age, Continuous(years)ActiveVehicleTotal
Mean37.96 ± 18.0941.56 ± 17.4239.73 ± 17.8
Sex: Female, Male
Sex: Female, Male(Participants)ActiveVehicleTotal
Female484391
Male333568
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ActiveVehicleTotal
Hispanic or Latino131629
Not Hispanic or Latino6555120
Unknown or Not Reported3710
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ActiveVehicleTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander112
Black or African American145
White7870148
More than one race000
Unknown or Not Reported033
Region of Enrollment
Region of Enrollment(participants)ActiveVehicleTotal
United States8178159
08

Study locations

16 sites
  • Aclaris Investigational Site
    Glendale, Arizona 85308, United States
  • Aclaris Investigational Site
    Fort Smith, Arkansas 72916, United States
  • Aclaris Investigational Site
    Encinitas, California 92024, United States
  • Aclaris Investigational Site
    Los Angeles, California 90045, United States
  • Aclaris Investigational Site
    Denver, Colorado 80210, United States
  • Aclaris Investigational Site
    Omaha, Nebraska 68144, United States
  • Aclaris Investigational Site
    Albuquerque, New Mexico 87106, United States
  • Aclaris Investigational Site
    Rochester, New York 14623, United States
  • Aclaris Investigational Site
    High Point, South Carolina 27262, United States
  • Aclaris Investigational Site
    Knoxville, Tennessee 37922, United States
  • Aclaris Investigational Site
    Nashville, Tennessee 37215, United States
  • Aclaris Investigational Site
    College Station, Texas 77845, United States
  • Aclaris Investigational Site
    Houston, Texas 77004, United States
  • Aclaris Investigational Site
    Salt Lake City, Utah 84117, United States
  • Aclaris Investigational Site
    Lynchburg, Virginia 24501, United States
  • Aclaris Investigational Site
    Norfolk, Virginia 23507, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Mar 2018, 7 months.

Results were first posted in Mar 2019, 1 year after primary completion.

Of 18 phase 2 interventional studies under Warts, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2017
First posted
Sep 11, 2017
StartActual
Jul 13, 2017
Primary completionActual
Mar 1, 2018
CompletionActual
Mar 1, 2018
Results first posted
Mar 29, 2019
Last update
Apr 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03278028
Responsible party
Sponsor
First posted
Sep 11, 2017
Start date
Jul 13, 2017
Primary completion
Mar 1, 2018
Completion
Mar 1, 2018
Results posted
Mar 29, 2019
Last update
Apr 9, 2019

Study contacts

Stuart D Shanler, MD
study director · Aclaris Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-phenylacetoaminomethylene-DL-p-nitrophenylalanine

Start the discussion